Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration

A Randomized, Controlled, Open-label, Parallel Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration

In China, the estimated prevalence of patients with ESRD receiving PD or maintenance HD increased from 51.7 per million population (pmp) at the end of 2007 to 79.1 pmp at the end of 2008. Theranova 400 is designed to deliver the performance of hemodiafiltration (HDF) using standard hemodialysis (HD) equipment and treatment mode, including HD machines, disposables, blood and dialysate flows, length of treatment and frequency of treatment. Theranova 400 utilizes a Medium Cut-Off (MCO) membrane with extended permeability for middle solutes to closely modulate the removal function of the kidney without the complexity of HDF. The primary objective of the study is to demonstrate non-inferiority of the Theranova Dialyzer in hemodialysis (HD) mode compared to hemodiafiltration (HDF), using FX 800 in HDF mode. Comparison of the study arms over time will be used to support the safety of Theranova 400 by demonstrating stable serum albumin levels, as well as support the dialyzer's efficacy to significantly remove serum middle molecules.

Study Overview

• Status: Completed
• Conditions: End Stage Renal Disease
• Intervention / Treatment: Device: Theranova 400 Dialyzer; Device: FX800 Dialyzer

• Study Type: Interventional
• Enrollment (Actual): 212
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100034
    • Baxter Investigational SIte
  • Anhui
    • Hefei, Anhui, China, 230601
      • Baxter Investigational SIte
  • Guangdong
    • Guangzhou, Guangdong, China, 510515
      • Baxter Investigational SIte
  • Henan
    • Zhengzhou, Henan, China, 450052
      • Baxter Investigational SIte
  • Hubei
    • Wuhan, Hubei, China, 430060
      • Baxter Investigational SIte
  • Shanghai
    • Shanghai, Shanghai, China, 200011
      • Baxter Investigational SIte
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Baxter Investigational SIte
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310014
      • Baxter Investigational SIte

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients aged 18 years or older.
• Patients who are able to give IC after an explanation of the proposed study.
• Patients who have Kt/Vurea > 1.2 for the last 2 measurements, with the most recent Kt/Vurea measurement taken within 4 weeks before or during study screening.
• Patients with a dialysis prescription (dialyzer, time, dialysis fluid flow rate (QD), blood flow rate (QB)) stable over 6 recent treatments. The dialysis treatment time should be 3.5 to 4.5 hours per session with minimum QB of at least 250 mL/min and QD of 500 mL/min.
• Patients who are on stable anticoagulation prescription and dose.
• Patients with ESRD receiving chronic HD treatment with a history of thrice weekly HD, and at least 1 HDF session within 1 month prior to study.
• Patients who have been stable on in-center HD for >3 months prior to study enrollment
• Patients who have an adequate arteriovenous (AV) fistula or graft, or dual-lumen tunneled catheter capable of providing a blood flow rate of at least 250 mL/min.
• Patients with a minimum total convective volume (including ultrafiltration (UF)) of 16 L post-dilution for the most recent HDF treatment.
• Patients who receive in-center treatment hemodialysis at a site that routinely implements high flux dialysis and HDF.

Exclusion Criteria:

• Patients who have acute renal failure with the chance for recovery.
• Patients who are pre-scheduled for a living donor kidney transplant within the next six months, who plan a change to PD within the next six months, or who require single-needle dialysis therapy.
• Pregnant and lactating women.
• Patients with positive serology tests for Hepatitis B surface antigen, Hepatitis C total antibody), HIV and Syphilis.
• Patients with known hemodynamic instability, anemia (Hgb < 90 g/L), and/or patients with Hgb >130g/L for coagulation risk.
• Patients who are severely malnourished or with significant disease that interferes with liver synthetic function, e.g. with serum albumin <35 g/L.
• Patients with active or ongoing infection as per investigator's judgement.
• Patients with history of solid tumors requiring anti-cancer therapy in the past or next 6 months, or life expectancy less than 1 year, or patients or with history of hematology neoplasm.
• Patients diagnosed with a NYHA Class IV congestive heart failure, or acute coronary syndrome and/or who have suffered a myocardial infarction within three months prior to the start of the study.
• Patients with a history of severe mental disorders.
• Patients who are currently participating in, or have previously participated in other interventional clinical trials during the past 4 weeks.
• Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone (PS) membrane or have history of poor tolerance to dialyzers with synthetic membranes
• Patients with advanced liver, heart or pulmonary disease as judged by the Investigator.
• Patients with any comorbidity possibly conflicting with the study purpose or procedures as judged by the Investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Theranova 400 Dialyzer; In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.	Device: Theranova 400 Dialyzer; Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
Active Comparator: FX800; In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.	Device: FX800 Dialyzer; Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction ratio of lambda free light chains (λ FLC)	At the first mid-week treatment day	Up to 1 week
Reduction ratio of β2 microglobulin	At the first mid-week treatment day	Up to 1 week
Pre-dialysis serum albumin		Study Completion (Week 12)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kt/V urea	Mid-Week Treatment Day	Week 1, Week 5, Week 9, Week 13
Urea reduction ratio (URR)	Mid-Week Treatment Day	Week 1, Week 5, Week 9, Week 13
Pre-dialysis serum levels of λ FLC	Mid-Week Treatment Day	Week 1, Week 5, Week 9, Week 13
Pre-dialysis serum levels of β2 microglobulin	Mid-Week Treatment Day	Week 1, Week 5, Week 9, Week 13
Reduction ratio of α1 microglobulin (α1M)	At the first mid-week treatment day	Up to 1 week
Reduction ratio of Chitinase-3-like protein (YKL-40)	At the first mid-week treatment day	Up to 1 week
Reduction ratio of complement factor D (CFD)	At the first mid-week treatment day	Up to 1 week
Reduction ratio of myoglobin	At the first mid-week treatment day	Up to 1 week
Reduction ratio of kappa free light chains (κ FLC)	At the first mid-week treatment day	Up to 1 week

Collaborators and Investigators

• Sponsor: Baxter Healthcare Corporation
• Investigators: Study Director: Baxter Clinical Trial, Baxter Healthcare

Study record dates

Study Major Dates

• Study Start (Actual): June 29, 2018
• Primary Completion (Actual): January 4, 2020
• Study Completion (Actual): January 4, 2020

Study Registration Dates

• First Submitted: May 16, 2018
• First Submitted That Met QC Criteria: June 4, 2018
• First Posted (Actual): June 6, 2018

Study Record Updates

• Last Update Posted (Actual): March 4, 2020
• Last Update Submitted That Met QC Criteria: March 2, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Renal Insufficiency, Chronic; Kidney Diseases; Kidney Failure, Chronic
• Other Study ID Numbers: 7408001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No